Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2019 August;110(4) > Minerva Medica 2019 August;110(4):301-19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  UPDATES IN OVARIAN CANCER AND SECONDARY PERITONEAL TUMORS 

Minerva Medica 2019 August;110(4):301-19

DOI: 10.23736/S0026-4806.19.06091-9

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Hereditary ovarian cancers: state of the art

Angela TOSS 1, Eleonora MOLINARO 1, Margaret SAMMARINI 2, Maria C. DEL SAVIO 2, Laura CORTESI 1, Fabio FACCHINETTI 2, Giovanni GRANDI 3

1 Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 2 Department of Medical and Surgical Sciences for Mother, Child and Adult, Polyclinic University Hospital, University of Modena and Reggio Emilia, Modena, Italy; 3 Unit of Obstetrics and Gynecology, Department of Obstetrics, Gynecology and Pediatrics, Polyclinic University Hospital, University of Modena and Reggio Emilia, Modena, Italy



The identification of a mutation in ovarian cancer (OC) predisposition genes plays a crucial role in the management of cancer prevention, diagnosis, and treatment. In healthy carriers, the detection of a specific mutation might justify more intensive and personalised surveillance programmes, chemopreventive measures, and prophylactic surgeries. Moreover, the identification of a mutation in affected OC patients might provide fundamental knowledge of the tumour pathogenesis, thus guiding treatment choices. This is a comprehensive review of the molecular pathways involved in the pathogenesis of hereditary ovarian cancers, the clinical-pathological features of these tumours, and the potential implications for their prevention and clinical management.


KEY WORDS: Hereditary breast and ovarian cancer syndrome; Poly(ADP-ribose) polymerase inhibitors; Peritoneal neoplasms

top of page